Skip to content

Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study

A Multi-center, Cluster-randomized, Prospective, Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03254914
Enrollment
3554
Registered
2017-08-21
Start date
2017-08-09
Completion date
2019-02-28
Last updated
2024-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Home Blood Pressure, Fimasartan

Brief summary

The purpose of this study is to evaluate the effect of home blood pressure monitoring on controlling blood pressure and correlation between home blood pressure and clinic blood pressure in hypertensive patients receiving two or more concomitant antihypertensive agents including fimasartan

Detailed description

A multi-center, cluster-randomized, prospective, observational study

Interventions

PROCEDUREHome Blood Pressure

Measure Home Blood Pressure

Sponsors

Boryung Pharmaceutical Co., Ltd
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects who voluntarily signed informed consent for participating in this clinical study * Male and female over the age of 19 * Hypertensive patients receiving two or more concomitant anti-hypertensive agents including fimasartan

Exclusion criteria

* Renal dialysis patients. * Diabetic nephropathy patients taking angiotensin-converting enzyme inhibitor. * Severe renal disorder * Subjects with hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. * Medical history with hypersensitivity to Fimasartan * Pregnant women or lactating female. * Participate in another clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Rate of reaching target blood pressure12 weeks after treatmentRate of reaching target blood pressure after treatment for 12 weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026